In 2021, CDHT concentrated on the construction of strong chain, complementary chain and extended chain of public technology platforms, focused on the weak fields of platforms such as photoelectric display, 5G and artificial intelligence, identified 21 public technology platforms with a number of national laboratory accreditation and industry accreditation qualifications and a large quantity of technical services software and hardware resources, and effectively solved the limitations of production, R&D and technological innovation of small and medium-sized technology-based enterprises.
Among the 21 newly identified platforms, there are 7 electronic information platforms, 5 new economy platforms, and 9 biological medicine platforms.
Among the 9 identified biological medicine platforms,
Chengdu Shilian Kangjian Biotechnology Co., Ltd.
at Chengdu Advanced Medical Science Center
is identified as
a public technology platform for R&D, application and transformation of stem cell technology
BIOTIANFU
at Chengdu Advanced Medical Science Center
a public technology platform for R&D, application and transformation of stem cell technology
Company Profile
Chengdu Shilian Kangjian Biotechnology Co., Ltd. was approved by the government of CDHT and founded by joint investment of Chengdu West China Cell Therapy Research Institute Co., Ltd. (West China Hospital, Sichuan University), Sichuan West China Maternal and Child Health Technology (West China Second University Hospital, Sichuan University), Sichuan West China Oral Health Technology Co., Ltd. (West China School / Hospital of Stomatology, Sichuan University), and the team of Prof. Tian Weidong - Chief Scientist of the National "973" Program and key R&D program. The Company built an international first-class and high-standard platform for cell technology and cell drug R&D and transformation at Chengdu Advanced Medical Science Center. Phase I platform construction has been completed, including cell information resource library (cell storage for tens of millions of people), regional cell preparation center with 6 independent cell production workshops that meet the highest international standards (preparation of adult stem cells, IPS cells and immune cells), and cell quality test center meeting third-party services. A quality system which is traceable in the whole cycle from cell preparation, detection to storage has been formed. Based on the existing resources and platforms, a high-tech biotechnology enterprise which features precision medicine and precision health and integrates cell technology R&D, achievement transformation, technical services and talent training is built.
Introduction to the public technology platform
The Public Technology Platform for R&D, Application and Transformation of Stem Cell Technology was built by Chengdu Shilian Kangjian Biotechnology Co., Ltd. in May 2021. Based on the R&D background of West China, cell storage center, cell preparation center and cell detection and evaluation center have been built for the platform, covering the whole R&D process of cell technology. Relying on “Evaluation on safety and efficacy of allogeneic dental sac stem cells in the treatment of periodontal bone defects: A parallel, prospective, randomized, controlled human multicenter clinical trial” applied by the Company together with West China School / Hospital of Stomatology, Sichuan University and eking University Hospital of Stomatology, the platform is expected to pass the approval of National Health Commission. Based on the existing resources and platforms, a high-tech biotechnology enterprise which features precision medicine and precision health and integrates cell technology R&D, achievement transformation, technical services and talent training is built.
Service item and cost
Contact
① Company address:
Building E7, Advanced Medical Science Center, Singapore-Sichuan High-tech Innovation Park, No. 16, Hemin Street, CDHT
② Website:
HTTP://WWW.CD-SLKJ.COM/
③ Contact:
Zhang 028-69333366 17341306357
BIOTIANFU
HitGen Inc.
Public Technology Platform for original new drug R&D, Analysis and Detection
Company Profile
HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA, which is engaged in new drug research and development. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (stock name: HitGen, ticker code 688222.SH). HitGen has established an internationally leading technology platform for discovery and optimization of small molecules and nucleic acid drugs, which centers on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contain more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing. HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS, e.g. protein expression and purification, structural biology, bioinformatics, and medicinal chemistry), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing.
Introduction to the public technology platform
The original new drug R&D analysis and testing platform is established by HitGen, currently located in Building C2 of Tianfu International Biotown. Adhering to the aim of “customer service orientation”, the platform has been engaged in chemical analysis and separation support since its setup in 2012. Except supporting internal demand, the platform also provides external services. Through the development for many years, the scale and capabilities of the platform continue to be expanded and strengthened. At present, the total area exceeds 2,000m2, and the platform has more than 50 large precision analytical instruments with a total value of over RMB 50 million. The platform now has more than 20 full-time professionals who use multiple means such as high performance liquid chromatography, liquid chromatography-mass spectrometry, automatic preparative liquid phase, nuclear magnetism, supercritical CO2 fluid chromatography to carry out analytical separation of small molecules, nucleic acids, proteins, peptides and other molecules, including purity detection, composition detection, structure identification, preparation and purification, overall supporting drug R&D and providing efficient technical services for customers.
The platform has four major capabilities:
(1) Analysis, characterization, separation and purification of DNA coded chemical library (DEL), including high-flux DNA reaction monitoring and analysis platform based on UPLC-MS; PREP-HPLC separation and purification of DEL raw materials and products; and affinity selection mass spectrometry screening (ASMS) of ODV validation of DEL library.
(2) Characterization and purification of nucleotide components of nucleoside nucleic acid, including purity analysis by HPLC, LC-MS and NANODROP; preparation of samples from milligram to gram level by MPLC and PREP-HPLC; and SIRNA purity analysis and characterization by a variety of analytical methods.
(3) Purity analysis, separation and purification of chiral and achiral compounds, including analysis of analytical and preparative SFC chiral compounds; enrichment and purification of chiral or achiral compounds by SFC, HPLC and LC-MS; structural analysis by NMR, high resolution LC-MS and GC-MS.
(4) Other special analysis and separation, including impurity purification and structure identification, non-variable mass spectrum analysis, QNMR absolute quantification, water content determination, and solvent residue determination.
Main equipment of the public technology platform
Supercritical fluid chromatograph (preparation), WATERS high-resolution quadrupole flight time tandem LCMS, high performance liquid mass spectrometry, Shimadzu liquid chromatography-mass spectrometry, nuclear magnetic resonance spectrometer, mass spectrometry-guided preparative liquid chromatography, WATERS LCMS, gas chromatograph-mass spectrometer, liquid chromatograph, Shimadzu evaporative light-scattering detector, Shimazu supercritical chromatography system, high-flux parallel evaporator, high pressure preparative chromatography system, GILSON liquid phase preparation HPLC, Preparative HPLC, LTQ XL+UPLC ion trap LCMS, new double-stage reverse osmosis table-type ultrapure water purification machine, deionized water purification machine, and COD ammonia nitrogen tester, etc.
Service item
① Separation and purification
● SFC separation and purification of achiral compounds
● Chiral resolution at the milligram level
● Separation and purification of small molecule compounds
● Separation and purification of nucleoside, nucleic acid, and nucleotide components
● Analytical separation of components such as DEL PRODUCTS, ADC and AOC
● Separation and purification of parallel synthesis products
② Content determination
● HPLC, UPLC, LC-MS, SFC and NMR analysis and content determination
● Determination of residual solvent content
● Determination of heavy metal content
● Determination of moisture content
③ Purification and structural identification of impurities
● Separation of impurities in products, intermediates and active ingredients (content range 0.1%-20%)
● Collection of one-dimensional and two-dimensional NMR, LC-MS, UV and FT-IR data, analysis and identification of the purified impurities
Service item and cost
(Analysis and detection categories are as follows. Preparation and purification are priced according to samples)
① Analytical testing and content determination are charged by type and number (The fee shall be determined according to the test type and requirements);
②Separation and purification categories are charged according to the target content and specific purification difficulty (The fee shall be determined according to the specific sample);
③ Special analysis is charged according to the difficulty and instrument requirements.
Contact
① Company address:
Building C2, No. 8, Dongyi Road, Huigu, Yong'an Town, Tianfu International Biotown, Chengdu
② Website:
HTTPS://WWW.HITGEN.COM/
③ Contact:
Cao 028-85197385-8145
BIOTIANFU
Chengdu Easton Biopharmaceuticals Co., Ltd.
Public Technology Platform for Drug Crystal Research and Achievement Transformation
Company Profile
Founded in 2009, Chengdu Easton Biopharmaceuticals Co., Ltd. is a high-tech pharmaceutical company which is driven by R&D and innovation and integrates R&D, manufacture and sale of chemical APIs, high-end chemical and biological drugs. The Company was listed at Shanghai Stock Exchange (stock name: Easton, stock code: 688513) in September 2020, with 6 wholly-owned subsidiaries and over 1,000 employees. The Company has four major core technologies: drug crystal integrated innovation and industrialization technology, integrated technology for structural design, synthesis and evaluation of innovative compounds, sustained-release technology and delayed-release technology, preparation process design and lean control technology. The Company has obtained the authorization of 87 domestic and foreign invention patents, including 15 international patents, and achieved the industrialization of more than 20 chemical pharmaceutical preparations and nearly 20 chemical API products. It has production lines of small volume injection, freeze-dried powder injection, tablet and hard capsule, and all the production lines have passed the new version of GMP production line, with a domestically leading drug quality control system which strongly ensures product pilot study and industrialization requirements.
Introduction to the public technology platform
The Public Technology Platform for Drug Crystal Research and Achievement Transformation is mainly engaged in drug crystal type detection and analysis, crystal type screening research, crystallization process research, drug pilot study, drug industrialization and other services, and has efficient crystal type screening technology, coupling crystallization technology of API industrialization based on quality control, and pharmaceutical preparation industrialization technology based on quality control, etc. Besides, the platform has a 6,500m2 test site, and 37 sets of high-end instruments and equipment with the original value of over RMB 16.2 million, including differential scanning calorimeter, X-ray powder diffractometer, thermogravimetric analyzer and gas chromatograph-mass spectrometer. The platform now has 72 team members, among which 37.50% are doctors/masters, and provides services in the whole industry chain from project approval, R&D to production, including drug crystal detection and analysis, crystal screening research, crystallization process research, drug pilot study and achievement transformation under GMP conditions.
Main equipment of the public technology platform
X-ray powder diffractometer, differential scanning calorimeter, thermogravimetric analyzer, and polarizing microscope, etc.
Service item
Provide crystal type detection and analysis, crystal type screening research, crystallization process research, drug pilot study, drug industrialization and other services.
Service item and cost
Contact
Company address:
No. 8, Xiyuan Avenue, CDHT
② Website:
HTTP://WWW.EASTONPHARMA.CN/
③ Contact:
Guan 13548059229
BIOTIANFU
Chengdu Yilukang Medical Technology Service Co., Ltd.
Public Technology Platform for Drug R&D and MAH
Company Profile
Founded in October 2008, Chengdu Yilukang Medical Technology Service Co., Ltd. has 13-year experience in drug R&D services. Since the MAH system was implemented, Yilukang has had more than 10 wholly-owned or cooperative investment projects. The service scope covers pharmaceutical MAH collaboration, pharmaceutical process development and preparation, clinical research, registration application, process optimization and quality improvement of marketed drugs, etc. The company provides integrated technical service platforms and new product system solutions. The technology platform was awarded the titles of "Intellectual Property Advantage Enterprise", “demonstration base and demonstration unit introducing foreign intellectual properties in Chengdu”, “Sichuan technology transfer demonstration institution”, “specialization, fine, characteristic, novel small and medium-sized enterprise” and “Gazelle Enterprise”.
Introduction to the public technology platform
The Public Technology Platform for Drug R&D and MAH has such departments as preparation, analysis, synthesis, pharmacology, clinical, registration, quality assurance (QA) and traditional Chinese medicine. The process management system of new drug project information collection, project approval, R&D and application and the systematic and complete new drug project R&D system have been established. In terms of drug R&D, a sound R&D quality management system ensures the success rate and efficiency of R&D. In terms of drug GMP, Yilukang has obtained the license for 11 dosage forms, and such scope of license is still expanding, providing a strong guarantee for drug quality management in the whole life cycle. Four characteristic technology platforms and three general technology platforms meet the R&D application requirements of different products.
Service item and cost
The platform has dozens of analytical equipment and preparation research equipment like LCMS, HPLC, gas chromatograph, and atomic absorption spectrometer as hardware and software support for different product quality research and process development.
Service item
① Drug prescription and process development-small-amount experiment-pilot whole chain R&D platform;
② Drug R&D quality management;
③ Delayed-release preparation development;
④ Drug MAH (marketing authorization holder) service.
Service item and cost
Contact
① Company address:
No. 3, keyuan South Road, CDHT
② Website:
WWW.YILUKANG.COM
③ Contact:
Tao 18980055456
BIOTIANFU
Chengdu Genegle Medical Laboratory Co., Ltd.
Public Technology Platform for Molecular Diagnosis and Gene Test
Company Profile
Chengdu Genegle Medical Laboratory Co., Ltd. (hereinafter referred to as Genegle) depends on Chengdu Genegle Bio-tech Co., Ltd. (founded in 2006) and US GENEGLE BIOTECHNOLOGY LLC. It is the earliest special medical laboratory in Sichuan (2012) featuring innovative services of gene testing and molecular diagnosis. The Company is committed to transforming and applying international cutting-edge high-flux molecular detection technologies, and creating a professional interdisciplinary medical team. The team of the Company was selected as Chengdu "Rongpiao Program" innovation and entrepreneurship team. As a high-tech enterprise, the Company has set up a Chengdu-centered cross-regional closed-loop medical service system, focuses on integrated production and research services for women's reproductive health, newborn disease screening, precise prevention and treatment of children's diseases, diagnosis and treatment of infectious diseases, cancer prevention and treatment and disease research, and provides cutting-edge technical support for early screening, diagnosis and treatment of diseases.
Introduction to the public technology platform
Service item
① Reproductive health: Focusing on women's and children's health, the company has advanced second generation sequencing, gene chip, tandem mass spectrometry and other detection technology platforms and can detect maternal, fetal, newborn and childhood diseases (such as recessive genetic disease, genetic metabolic disease, severe combined immunodeficiency, congenital deafness, and nutritional status (such as vitamin deficiency and anemia). The expert consulting team can provide one-stop disease solutions.
② Infectious diseases: In response to the clinical requirements of "multi-tests of one sample, accuracy and efficiency", Genegle set up multi-level and multi-platform infectious disease detection services to provide one-stop solutions for different clinical requirements.
③ Nutrition medication: Provide customers with accurate gene detection results rapidly, and carry out comprehensive, continuous and active management to promote health, delay the process of chronic diseases, reduce complications, prolong life, improve the quality of life and reduce medical costs.
④ Tumor prevention and treatment: Through the second-generation sequencing technology, immunity, genetic tumor, early tumor molecular signal can be detected for individuals from the molecular level, and tumor risks can be comprehensively evaluated. Mutation gene detection is conducted for specific high-risk groups and individuals, and effective prevention and treatment or intervention is carried out for carriers to prevent the occurrence of cancer.
Contact
① Company address:
Building A, Innovation Center, No. 5, Gaopeng Avenue, CDHT
② Website:
YX.GENEGLE.COM
③ Contact:
Gao 18139209517
BIOTIANFUBI
Sichuan Institute for Drug Control
(Sichuan Medical Instrument Testing Center)
Sichuan Institute for Drug Control (Sichuan Medical Instrument Testing Center) is a public institution directly under Sichuan Medical Products Administration. Besides, it is also an inspection institution for imported drugs (including biological products) at Chengdu port, the biological products batch issuing and inspection organization authorized by National Medical Products Administration (blood products, live attenuated Japanese encephalitis vaccine, COVID-19 inactivated vaccine), drug GLP institution, cosmetics registration and filing inspection and testing institution, and cosmetics sampling inspection and re-inspection agency. The Institute has established and implemented a sound quality system, and obtained national and provincial qualification certification (national and provincial CMA), laboratory accreditation (CNAS), SPF animal room qualification certificate, and several secondary biological safety laboratory registration certificates. The Institute has systematic software and hardware inspection and testing equipment and a professional technical service team, and can undertake the inspection, testing and technical research of drugs (including biological products), packaging materials and containers directly contacting drugs, pharmaceutical excipients, medical instruments and cosmetics, etc.
Public Technology Platform for Chinese Patent Medicine Quality Evaluation
Introduction to the public technology platform
The Public Technology Platform for Chinese Patent Medicine Quality Evaluation is composed of 4 departments of Sichuan Institute for Drug Control (Sichuan Medical Instrument Testing Center): Laboratory of Traditional Chinese Medicine (Ethnic Medicine), Microbiological Laboratory, Safety Evaluation Center, and Laboratory of Drug Packaging Material Testing and Drug Compatibility. The existing laboratory area is about 7,869.8m2. The platform has all kinds of high-grade, precision and advanced analytical instruments such as ion chromatography-inductively coupled plasma mass spectrometry and fluorescence quantitative PCR. The staff of the platform mainly graduated from Peking University, Fudan University and other well-known universities, with good technical level and research ability. The platform makes the most of its advantages and experience in the research field of traditional Chinese medicine (including Chinese medicinal materials and decoction pieces, extracts, Chinese patent medicine and ethnic medicine). The platform can provide technical consultation and technical services in quality evaluation and quality standard study of traditional Chinese medicine, safety evaluation study of traditional Chinese medicine, residual analysis and risk assessment study of exogenous pollutants (pesticides, heavy metals, mycotoxins, and harmful microorganisms).
Main equipment of the public technology platform
Ion chromatography-inductively coupled plasma mass spectrometry, fluorescence quantitative PCR, automatic pathogen detection system, thin layer chromatography scanner, liquid chromatography-mass spectrometry, automatic bacterial identification and drug sensitivity analysis system, matrix assisted laser desorption ionization flight time mass spectrometry, gas chromatograph-mass spectrometer, and biological confocal laser scanning microscope, etc.
Service item
Contact
① Company address:
Building E7, Advanced Medical Science Center, Singapore-Sichuan High-tech Innovation Park, No. 16, Hemin Street, CDHT
② Website:
HTTP://WWW.CD-SLKJ.COM/
③ Contact:
Zhang 028-69333366 17341306357
Public Technology Platform for Technical Services of Drug Preparation in Vitro and in Vivo Correlation
Introduction to the public technology platform
The Public Technology Platform for Technical Services of Drug Preparation in Vitro and in Vivo Correlation is composed of 5 departments of Sichuan Institute for Drug Control (Sichuan Medical Instrument Testing Center): Chemicals Laboratory, Biological Sample Testing Center, Microbiological Laboratory, Safety Evaluation Center, and Laboratory of Drug Packaging Material Testing and Drug Compatibility. The existing laboratory area is about 8,065.8 m2. There is Drug solubility-permeability determination laboratory, and drug physicochemical laboratory. The platform has all kinds of high-grade, precision and advanced analytical instruments such as liquid chromatography/mass spectrometry (LC/MS), gas chromatograph-mass spectrometer (GC/MS), PION solubility multifunctional tester and automatic liquid disposal workstation. The technical staff of the platform mainly graduated from Peking University, University of Tokyo, Sichuan University, China Pharmaceutical University and other well-known universities, with good technical level and research ability. The platform makes the most of the equipment advantages and technology advantages of the team, and can provide technical consultation and services in bioequivalence study, pharmaceutical preparation quality analysis and standards, pharmaceutical preparation safety evaluation and other aspects.
Main equipment of the public technology platform
Drug solubility and permeability tester, inductively coupled plasma source mass spectrometer, automatic dissolution tester, pipetting workstation, milk particle distribution measuring instrument, liquid mass spectrometer 5500, scale (millionth), automatic liquid disposal workstation, GC-MS, ANDERSEN cascade impactor, NGI cascade impactor, X-ray diffractometer, and ion chromatograph, etc.
Service item
Contact
① Company address:
No. 8, Xinwen Road, Chengdu Hi-Tech Industrial Development West Zone
② Website:
HTTPS://WWW.SCSYJS.ORG/
③ Contact:
Luo 028-87877186
Public Technology Platform for Quality Evaluation and Standard Study of Medical Instruments
Introduction to the public technology platform
The Public Technology Platform for Quality Evaluation and Standard Study of Medical Instruments is composed of 3 departments of Sichuan Institute for Drug Control (Sichuan Medical Instrument Testing Center): Active Instrument Testing Office, Passive Instrument Testing Office and Safety Evaluation Center. The existing laboratory area is about 9,835m2. There is electromagnetic compatible half-wave anechoic chamber, X-ray shielding room, high frequency surgical equipment laboratory, and medical device reliability laboratory. The platform has all kinds of high-grade, precision and advanced analytical instruments such as liquid chromatography-electrostatic field orbital trap high-resolution mass spectrometer, and X-ray diffraction analyzer. The staff of the platform mainly graduated from Peking University, Fudan University, Sichuan University, University of Electronic Science and Technology of China, China Pharmaceutical University and other well-known universities, with good technical level and research ability. The platform makes the most of its advantages and experience in the field of medical instrument research, and can provide technical consultation and technical services in the fields of medical instrument testing, standard and test method research, technical training for testing personnel, and production quality management system, etc.
Main equipment of the public technology platform
Electromagnetic compatibility laboratory system, liquid chromatography-electrostatic field orbital trap high-resolution mass spectrometer, X-ray diffractometer, atomic force microscope, EMI test system - receiver, microwave test system, walk-in constant temperature and humidity chamber, inductively coupled plasma source mass spectrometer, differential scanning calorimeter, microthermal analyzer, fatigue mechanical properties testing system, ultrasonic field distribution detection system, automatic filter material tester, X-ray fluorescence spectrometer of energy scattering type, and oxygen nitrogen hydrogen analyzer.
Service item
Contact
① Company address:
No. 8, Xinwen Road, Chengdu Hi-Tech Industrial Development West Zone
② Website:
HTTPS://WWW.SCSYJS.ORG/
③ Contact:
Pi 028-64020236
Public Technology Platform for Quality Evaluation of Vaccines and Biological Products
Introduction to the public technology platform
The Public Technology Platform for Quality Evaluation of Vaccines and Biological Products is composed of 4 departments of Sichuan Institute for Drug Control (Sichuan Medical Instrument Testing Center): Biological Product Inspection Office, Microbiological Laboratory, Safety Evaluation Center, and Laboratory of Drug Packaging Material Testing and Drug Compatibility. The existing laboratory area is about 7,644.6m2. There is cell laboratory, virus laboratory, microbial examination room, immunity laboratory, and secondary biosafety laboratory, etc. The platform has all kinds of high-grade, precision and advanced analytical instruments such as UPLC high-resolution mass spectrometer, and MICRO CT for small animals. The platform staff mainly graduated from Peking University, Sichuan University, Wuhan University, China Pharmaceutical University and other well-known universities, with good technical level and research ability. The platform makes the most of the advantages and experience in the field of vaccine and biological product research, and can provide technical consultation and services in quality testing and evaluation of vaccines and biological products, quality standard system research, and professional technical ability training, etc.
Main equipment of the public technology platform
UPLC high-resolution mass spectrometer, MICRO CT for small animals, GC-MS, automatic hematology analyzer, automatic biochemical immune system, full column imaging capillary electrophoresis apparatus, grain size analysis system, specific protein analyzer, ion chromatograph (IC), automatic bacteria identification instrument, automatic biochemical identification instrument for microorganism, and liquid chromatograph, etc.
Service item
Contact
① Company address:
No. 8, Xinwen Road, Chengdu Hi-Tech Industrial Development West Zone
② Website:
HTTPS://WWW.SCSYJS.ORG/
③ Contact:
Luo 028-87877186
Source: Chengdu Innovation and Entrepreneurship Service Center of CDHT
Park WeiChart